0000950170-24-064561.txt : 20240524 0000950170-24-064561.hdr.sgml : 20240524 20240524160534 ACCESSION NUMBER: 0000950170-24-064561 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20240522 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20240524 DATE AS OF CHANGE: 20240524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SPRUCE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001683553 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812154263 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39594 FILM NUMBER: 24984258 BUSINESS ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 740 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (415) 655-4168 MAIL ADDRESS: STREET 1: 611 GATEWAY BOULEVARD, SUITE 740 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 8-K 1 sprb-20240522.htm 8-K 8-K
0001683553false00016835532024-05-222024-05-22

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 22, 2024

Spruce Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39594

81-2154263

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

611 Gateway Boulevard, Suite 740

South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (415) 655-4168

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

SPRB

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On May 22, 2024, Spruce Biosciences, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 25, 2024, the record date for the Annual Meeting, 41,152,616 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

 

Proposal 1. Election of Directors

The Company’s stockholders elected the two persons listed below as Class I Directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows:

 

Votes For

Votes Withheld

Broker
Non-Votes

Tiba Aynechi, Ph.D.

19,761,274

 

 

639,508

 

 

10,667,525

Kirk Ways, M.D., Ph.D.

19,286,428

 

 

1,114,354

 

 

10,667,525

 

Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The final voting results are as follows:

 

Votes For

Votes Against

Abstentions

Broker
Non-Votes

30,581,608

436,679

50,020

-

 

 

 

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

SPRUCE BIOSCIENCES, INC.

Date: May 24, 2024

By:

/s/ Samir Gharib

Samir Gharib

President and Chief Financial Officer

 

 

 

 EX-101.SCH 2 sprb-20240522.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Central Index Key Entity Central Index Key Entity Address, State or Province Entity Address, State or Province Cover [Abstract] Entity Address, Address Line One Entity Address, Address Line One Amendment Flag Amendment Flag Entity Address, City or Town Entity Address, City or Town Document Type Document Type Title of 12(b) Security Title of 12(b) Security Soliciting Material Soliciting Material Entity Address, Address Line Two Entity Address, Address Line Two Document Period End Date Document Period End Date Trading Symbol Trading Symbol Pre-commencement Tender Offer Pre-commencement Tender Offer Security Exchange Name Security Exchange Name Written Communications Written Communications Entity Ex Transition Period Entity Ex Transition Period Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number City Area Code City Area Code Local Phone Number Local Phone Number XML 4 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Document and Entity Information
May 22, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 22, 2024
Entity Registrant Name Spruce Biosciences, Inc.
Entity Central Index Key 0001683553
Entity Emerging Growth Company true
Entity Ex Transition Period false
Entity File Number 001-39594
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 81-2154263
Entity Address, Address Line One 611 Gateway Boulevard
Entity Address, Address Line Two Suite 740
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 415
Local Phone Number 655-4168
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol SPRB
Security Exchange Name NASDAQ
EXCEL 5 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 6 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 7 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 9 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sprb-20240522.htm sprb-20240522.xsd http://xbrl.sec.gov/dei/2024 false false JSON 11 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sprb-20240522.htm": { "nsprefix": "sprb", "nsuri": "http://www.sprucebiosciences.com/20240522", "dts": { "inline": { "local": [ "sprb-20240522.htm" ] }, "schema": { "local": [ "sprb-20240522.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_263407ed-34ed-4756-b735-ad430fac8b50", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sprb-20240522.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_263407ed-34ed-4756-b735-ad430fac8b50", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sprb-20240522.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.sprucebiosciences.com/20240522/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 12 0000950170-24-064561-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-064561-xbrl.zip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sprb-20240522_htm.xml IDEA: XBRL DOCUMENT 0001683553 2024-05-22 2024-05-22 0001683553 false 8-K 2024-05-22 Spruce Biosciences, Inc. DE 001-39594 81-2154263 611 Gateway Boulevard Suite 740 South San Francisco CA 94080 415 655-4168 false false false false Common Stock, par value $0.0001 per share SPRB NASDAQ true false